Holen Sie sich die Stockscreener-App
0.50
16.17%
0.0696
Vorhandelsmarkt:
.47
-0.03
-6.00%
Fractyl Health Inc Aktie (GUTS) Neueste Nachrichten
Fractyl Health Faces Significant Compliance Risks Under Global Anti-Corruption and Sanctions Laws - TipRanks
BofA Securities Maintains Fractyl Health(GUTS.US) With Buy Rating - Moomoo
Fractyl Health (GUTS) Stock Jumps 21% After Hours: Here's What You Should Know - Benzinga
Fractyl Health Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Fractyl Health Inc (GUTS) Q4 2025 Earnings Call Highlights: Navigating Financial Challenges ... By GuruFocus - Investing.com Canada
Fractyl Health outlines 2026 De Novo submission plans with pivotal Revita data expected in early Q4 - MSN
Disease-Modifying Therapies for Obesity and Type 2 Diabetes: Revita and Rejuva Pipeline Overview - Minichart
Fractyl Health Inc’s 2025 Q4 Call: CPT Code Timing, Regulatory Readiness, and Ablation Targets Don’t Align - Bitget
GUTS: Pivotal study enrollment complete; Revita advances toward key 2026 data and de novo submission - TradingView
Fractyl Health Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Fractyl Health Q4 2025 sees cost cut, stock dips - Investing.com
Fractyl Health (NASDAQ:GUTS) Posts Narrower-Than-Expected Loss Ahead of Pivotal Trial Readout - ChartMill
FRACTYL HEALTH ($GUTS) Releases Q4 2025 Earnings - Quiver Quantitative
Fractyl Highlights Revita Progress and 2025 Financial Results - TipRanks
Fractyl Health (NASDAQ:GUTS) Releases Earnings Results, Misses Expectations By $0.13 EPS - MarketBeat
Fractyl Health Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates - The Manila Times
Fractyl Health 2025 10-K: $0M Revenue, Net Loss $140.954M - TradingView
Fractyl Health (NASDAQ: GUTS) outlines Revita device and Rejuva gene therapy plans - Stock Titan
Fractyl Health (Nasdaq: GUTS) widens 2025 loss but advances pivotal Revita - Stock Titan
If You Invested $1,000 in Fractyl Health (GUTS) - Stock Titan
Fractyl Health, Inc. (GUTS) loses 77.6% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Fractyl Health (NASDAQ:GUTS) - intelligentinvestor.com.au
H.C. Wainwright Maintains a Buy Rating on Fractyl Health, Inc. (GUTS) with an $8 Price Target - Insider Monkey
Fractyl Health, Inc. (GUTS) moves to buy: Rationale behind the upgrade - MSN
Fractyl Health Receives Nasdaq Minimum Bid Price Notice - The Globe and Mail
Fractyl Health (Nasdaq: GUTS) faces Nasdaq minimum bid-price warning - Stock Titan
Portfolio Shifts: Is Fractyl Health Inc undervalued by DCF analysis2026 Chart Watch & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Fractyl Health to report fourth quarter and full year 2025 financial results and provide business updates on March 24, 2026 - marketscreener.com
Fractyl Health To Report Fourth Quarter And Full Year 2025 Financial Results And Provide Business Updates On March 24, 2026 - TradingView
Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Updates on March 24, 2026 - The Manila Times
Investment Report: What is the dividend yield of Fractyl Health Inc2026 Valuation Update & Growth Oriented Trade Recommendations - baoquankhu1.vn
Fractyl Health, Inc. (GUTS) Initiates Purchase: Reasons for the Rating Increase - Bitget
Rosalind Advisors Inc. Takes Position in Fractyl Health, Inc. $GUTS - MarketBeat
Does Fractyl Health Inc have pricing powerMarket Growth Review & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Fractyl Health announces proposed public offering - MSN
Aug Reactions: What is the dividend yield of Fractyl Health IncWeekly Stock Recap & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Fractyl Health, Inc. (NASDAQ:GUTS) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
GUTS Technical Analysis & ETF Price Forecast - Intellectia AI
GUTS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Fractyl Health Inc expected to post a loss of 18 cents a shareEarnings Preview - TradingView
Fractyl Completes Randomization in REMAIN-1 Revita Trial - The Globe and Mail
Fractyl Health completes randomization in Remain-1 pivotal cohort of Revita® - marketscreener.com
Fractyl Health Completes Randomization In Remain-1 Pivotal Cohort Of Revita® - TradingView
Fractyl Health completes randomization in REMAIN-1; topline 6-month data due early Q4 2026 - TradingView
Fractyl Health (GUTS) hits Revita pivotal trial milestone, eyes 2026 FDA filing - Stock Titan
Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita® for Post-GLP-1 Weight Maintenance - GlobeNewswire
Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita for Post-GLP-1 Weight Maintenance - Bitget
GUTS SEC FilingsFractyl Health 10-K, 10-Q, 8-K Forms - Stock Titan
Fractyl Health, Inc. (GUTS) Loses 77.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Finviz
Fractyl Health (GUTS) Projected to Post Quarterly Earnings on Monday - MarketBeat
Should I buy Fractyl Health, Inc. (GUTS) - Zacks Investment Research
GUTSFractyl Health Latest Stock News & Market Updates - Stock Titan
What is the PEG ratio of Fractyl Health Inc.July 2025 Technicals & Expert-Curated Trade Recommendations - mfd.ru
Alyeska discloses 4.97% Fractyl Health (GUTS) stake in ownership filing - Stock Titan
Fractyl Health plummets on data for Revita for weight loss maintenance - MSN
Short Interest in Fractyl Health, Inc. (NASDAQ:GUTS) Increases By 22.6% - MarketBeat
Insider Sell: What is the dividend yield of Fractyl Health IncJuly 2025 Final Week & AI Driven Price Predictions - baoquankhu1.vn
Decliners Report: How correlated is Fractyl Health Inc to the S P5002025 Momentum Check & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Aug Technicals: Does Fractyl Health Inc have pricing powerJuly 2025 EndofMonth & Long Hold Capital Preservation Plans - baoquankhu1.vn
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):